全文获取类型
| 收费全文 | 79252篇 |
| 免费 | 4315篇 |
| 国内免费 | 233篇 |
专业分类
| 耳鼻咽喉 | 981篇 |
| 儿科学 | 3148篇 |
| 妇产科学 | 1526篇 |
| 基础医学 | 10724篇 |
| 口腔科学 | 2417篇 |
| 临床医学 | 5931篇 |
| 内科学 | 18673篇 |
| 皮肤病学 | 2351篇 |
| 神经病学 | 7139篇 |
| 特种医学 | 2203篇 |
| 外国民族医学 | 4篇 |
| 外科学 | 10482篇 |
| 综合类 | 661篇 |
| 一般理论 | 43篇 |
| 预防医学 | 6229篇 |
| 眼科学 | 2069篇 |
| 药学 | 4472篇 |
| 4篇 | |
| 中国医学 | 378篇 |
| 肿瘤学 | 4365篇 |
出版年
| 2023年 | 608篇 |
| 2022年 | 833篇 |
| 2021年 | 2278篇 |
| 2020年 | 1210篇 |
| 2019年 | 2099篇 |
| 2018年 | 3073篇 |
| 2017年 | 1931篇 |
| 2016年 | 1841篇 |
| 2015年 | 1949篇 |
| 2014年 | 2360篇 |
| 2013年 | 3529篇 |
| 2012年 | 5784篇 |
| 2011年 | 6198篇 |
| 2010年 | 3196篇 |
| 2009年 | 2478篇 |
| 2008年 | 5020篇 |
| 2007年 | 5222篇 |
| 2006年 | 4768篇 |
| 2005年 | 4741篇 |
| 2004年 | 4369篇 |
| 2003年 | 4158篇 |
| 2002年 | 3747篇 |
| 2001年 | 1927篇 |
| 2000年 | 2307篇 |
| 1999年 | 1402篇 |
| 1998年 | 541篇 |
| 1997年 | 417篇 |
| 1996年 | 363篇 |
| 1995年 | 327篇 |
| 1994年 | 283篇 |
| 1993年 | 278篇 |
| 1992年 | 322篇 |
| 1991年 | 287篇 |
| 1990年 | 254篇 |
| 1989年 | 223篇 |
| 1988年 | 239篇 |
| 1987年 | 207篇 |
| 1986年 | 172篇 |
| 1985年 | 190篇 |
| 1984年 | 203篇 |
| 1983年 | 154篇 |
| 1982年 | 149篇 |
| 1981年 | 129篇 |
| 1980年 | 116篇 |
| 1979年 | 128篇 |
| 1978年 | 129篇 |
| 1977年 | 103篇 |
| 1976年 | 100篇 |
| 1975年 | 100篇 |
| 1973年 | 120篇 |
排序方式： 共有10000条查询结果，搜索用时 0 毫秒
1.
2.
3.
4.
Qiaojie Wang Karan Goswami Noam Shohat Arash Aalirezaie Jorge Manrique Javad Parvizi 《The Journal of arthroplasty》2019,34(5):947-953
Background
Whether prolonged operative time is an independent risk factor for subsequent surgical site infection (SSI) and periprosthetic joint infection (PJI) following total joint arthroplasty (TJA) remains a clinically significant and underexplored issue. The aim of this study is to investigate the association between operative time and the risk of subsequent SSI and PJI in patients undergoing primary TJA.Methods
We retrospectively reviewed 17,342 primary unilateral total knee arthroplasty and total hip arthroplasty performed at a single institution between 2005 and 2016, with a minimum follow-up of 1 year. A multivariate logistic regression model was conducted to identify the association between operative time and the development of SSI within 90 days and PJI within 1 year.Results
Overall, the incidence of 90-day SSI and 1-year PJI was 1.2% and 0.8%, respectively. Patients with an operative time of >90 minutes had a significantly higher incidence of SSI and PJI (2.1% and 1.4%, respectively) compared to cases lasting between 60 and 90 minutes (1.1% and 0.7%), and those lasting ≤60 minutes (0.9% and 0.7%, P < .01). In the multivariate model, the risk for infection increased by an odds ratio of 1.346 (95% confidential interval 1.114-1.627) for 90-day SSI and 1.253 (95% confidential interval 1.060-1.481) for 1-year PJI for each 20-minute increase in operative time.Conclusion
In patients undergoing primary TJA, each 20-minute increase in operative time was associated with nearly a 25% increased risk of subsequent PJI. We advocate that surgeons pay close attention to this underappreciated risk factor while maintaining safe operative practices, which minimize unnecessary steps and wasted time in the operating room. 相似文献5.
6.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献7.
8.
9.
Mirella Stuivenga Erik J. Giltay Olivia Cools Laurence Roosens Hugo Neels Bernard Sabbe 《Expert opinion on pharmacotherapy》2019,20(3):251-260
Introduction: Major Depressive Disorder (MDD) and General Anxiety Disorder (GAD) significantly contribute to the global burden of disease. Vilazodone, a combined serotonin reuptake inhibitor and 5-HT1A partial agonist, is an approved therapy for the treatment of MDD and which has been further investigated for GAD.
Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxiety disorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the Cochrane Library.
Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However, vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclear whether the drug’s dual mechanism of action provides greater efficacy than prevailing treatment options. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety in larger and more diverse populations. Although vilazodone may have an additional advantage for the treatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacy over and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodone should be considered as a second- or third-line treatment option for MDD and GAD. 相似文献
10.
Ángela M. Ortega-Galán M. Dolores Ruiz-Fernández Rocío Ortiz-Amo José Cabrera-Troya Inés M. Carmona-Rega Olivia Ibáñez-Masero 《Enfermería clínica》2019,29(1):10-17